Lancashire and South Cumbria
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-03 Erythropoietin
Darbepoetin Alfa
Aranesp
®
Formulary
Injection prefilled syringe 10micrograms, 30micrograms, 50micrograms
Injection prefilled syringe and SureClick 20micrograms, 40micrograms, 60micrograms, 80micrograms, 100micrograms.
Consultant initiation only
Epoetin alfa
Eprex
®
Formulary
Injection prefilled syringe 10,000units, 40,000units
Consultant initiation only
Links
LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
NICE NG203: Chronic kidney disease: assessment and management
NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
NICE TA1010: Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA323: Epoetin and darbepoetin for anaemia in people having chemotherapy
NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA698:Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease
Key
Full Site